Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Options for the four newly hired employees have a $3.71 exercise price, vest over four years, and carry a 10-year term subject to continued service.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Zentalis Pharmaceuticals (Nasdaq: ZNTL) granted non-qualified stock options to purchase an aggregate of 269,000 shares of common stock to four newly hired employees on September 1, 2026. According to Zentalis, the awards were issued under its 2022 Employment Inducement Incentive Award Plan in line with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $3.71 per share, equal to the closing price on the grant date, and a 10-year term. Vesting occurs over four years: 25% on the first anniversary of the vesting commencement date, then the remaining 75% in equal monthly installments over the following three years, subject to continued service.
Details
News Market Reaction – ZNTL
On Sep 2, the first trading day after this news, ZNTL closed 1.75% above the previous close. Our momentum scanner recorded 4 alerts for this stock that day. Relative volume reached 3.6x the daily average during tracking.
Data tracked by StockTitan Argus for the Sep 2 session.
Key Figures
- Options granted
- 269,000 shares
- Aggregate grant to four newly hired employees
- New employees
- Four employees
- Recipients of the inducement grants
- Exercise price
- $3.71 per share
- Equal to the closing price on the grant date
- Option term
- 10 years
- Term of the stock options
- Vesting period
- Four years
- Total vesting schedule
- Initial vesting
- 25%
- Vests on the first anniversary
- Remaining vesting
- 75%
- Vests in equal monthly installments thereafter
- Remaining vesting period
- Three years
- Period for monthly vesting installments
Historical Context
-
Public offering closed with 26,450,000 shares issued at $3.50 each.
-
Company priced 23,000,000-share offering at $3.50 per share.
-
Company proposed common-stock and pre-funded-warrant financing.
-
Second-quarter results included a $42.3 million net loss.
-
Options covering 84,000 shares went to two newly hired employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
wee1 inhibitor medical
non-qualified stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on September 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 269,000 shares of the Company’s common stock to four (4) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s entering into employment with Zentalis in accordance with Nasdaq Listing Rule 5635(c)(4).
The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Zentalis, or following a bona fide period of non-employment, as an inducement material to each such individual’s entering into employment with Zentalis, pursuant to Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price of
Vesting of the stock options is subject to the employee’s continued service to Zentalis on each vesting date.
About Zentalis Pharmaceuticals
Zentalis is a clinical oncology innovator developing a treatment approach for ovarian cancer and multiple tumor types. Leveraging therapeutics development and biomarker expertise, Zentalis is advancing monotherapy and combination studies of its investigational first-in-class WEE1 inhibitor, azenosertib. Focused on translating WEE1 science into clinical practice, we aim to equip physicians with a targeted, non-chemo, orally available medicine that enhances treatment experience, choice, and outcomes. Our mission: to unburden cancer patients with more convenience and care.
For more information, please visit www.zentalis.com. Follow Zentalis on LinkedIn at www.linkedin.com/company/zentalis-pharmaceuticals.
ZENTALIS® and its associated logo are trademarks of Zentalis and/or its affiliates. All website addresses and other links in this press release are for information only and are not intended to be an active link or to incorporate any website or other information into this press release.
Contact:
Aron Feingold
VP, Investor Relations & Corporate Communications
ir@zentalis.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.